Gilead Sciences, Inc. (GILD) operating KPIs
GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 11/30105% above fair value
$170.68+5.07 (+3.06%)
Close on Oct 30, 2026Market cap $211.64BP/E –Yield 1.85%
Gilead Sciences non-GAAP Free cash flow (Form 8-K Selected Cash Flow Information, $M) ($M)
Form 8-K Selected Cash Flow Information
Latest, FY2025
9,456
Period ended Dec 31, 2025
Change on a year earlier
-8.2%
10,305 in FY2024
History
6 years
Since FY2020
Sources
5
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Non-GAAP Free cash flow (Form 8-K Selected Cash Flow Information, $M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 9,456 | -8.2% | Form 8-K (exhibit991earningspressrel.htm, filed 2026-02-10) ↗ |
| FY2024 | Dec 31, 2024 | 10,305 | +38.9% | Form 8-K (exhibit991earningspressrel.htm, filed 2026-02-10) ↗ |
| FY2023 | Dec 31, 2023 | 7,421 | -11.1% | Form 8-K (exhibit991earningspressrel.htm, filed 2025-02-11) ↗ |
| FY2022 | Dec 31, 2022 | 8,344 | -22.8% | Form 8-K (exhibit991earningspressrel.htm, filed 2024-02-06) ↗ |
| FY2021 | Dec 31, 2021 | 10,805 | +43.7% | Form 8-K (exhibit991earningspressrel.htm, filed 2023-02-02) ↗ |
| FY2020 | Dec 31, 2020 | 7,518 | – | Form 8-K (exhibit991earningspressrel.htm, filed 2022-02-01) ↗ |
Breakdown
What makes up non-gaap free cash flow (form 8-k selected cash flow information, $m)
Cite this data
StockData. (2026). Gilead Sciences Non-GAAP Free cash flow (Form 8-K Selected Cash Flow Information, $M) ($M), annual FY2020–FY2025 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/rel_fcf_row
See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.